SectorBiological Technology
Established Date--
Listing Date30/04/2021
ExchangeNASDAQ Stock Exchange
Full-time Employees14
Fiscal Year Ends31/12
Security TypeDepository Receipts (Ordinary Shares)
Office address20400 Century Blvd, Suite 210, Germantown, MD 20874
Business
IntroductionBarinthus Biotherapeutics plc is a public limited company incorporated under the laws of England and Wales in March 2021. The company is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy candidates for autoimmune and inflammatory diseases. Its lead drug candidate, VTP-1000, utilizes its proprietary SNAP-TI platform to promote immune tolerance in celiac disease, while VTP-300 utilizes viral vector technology to target chronic hepatitis B.
